Alector, Inc. ALEC

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)). $172.8 million in cash, cash equivalents and investments provide runway at least through 20

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

Alector’s latest update leaves the model fair value steady at US$3.10 per share, so headline price target assumptions are unchanged even as inputs inside the model continue to move. Analysts are linking this steady fair value to shifting sentiment around tau-targeting therapies in Alzheimer’s, where the CELIA dataset and broader MAPT readthroughs are feeding directly into how they weigh upside potential against execution risk. As you read on, you will see how these crosscurrents shape the...

Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) $206.5 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Cali

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies. Separately, GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis. The company has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda. GSK,...

Alector’s refreshed analyst narrative comes with $6 price targets that are presented as more closely aligned with the company’s current therapeutic pipeline and BBB shuttle focus. Research notes link these $6 targets to a cleaner story after the frontotemporal dementia trial, with a stronger spotlight on neurodegeneration mechanisms and protein engineering strengths, alongside ongoing execution and clinical risks. As you read on, you will see how this evolving setup might shape your own view...

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer’s disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson’s disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SA

Alector’s latest analyst update moves its modeled fair value from US$2.10 to US$2.88, a shift that sits between a bullish US$6 target and a bearish US$0.90 view. Both sides are reacting to the same pivot toward BBB shuttle therapeutics, but while optimistic analysts see a clearer, more focused story, cautious voices still emphasize execution risk and past trial setbacks. As you read on, you will see how to track this evolving narrative and what to watch as sentiment around Alector continues...